Brain and Systemic Inflammation in De Novo Parkinson's Disease

Overview

Journal Mov Disord

Date 2023 Feb 28

PMID 36853618

Authors

Talene A Yacoubian

Yu-Hua Dean Fang

Adam Gerstenecker

Amy Amara

Natividad Stover

Lauren Ruffrage

Christopher Collette

Richard Kennedy

Yue Zhang

Huixian Hong

Hongwei Qin

Jonathan McConathy

Etty N Benveniste

David G Standaert

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the presence of brain and systemic inflammation in subjects newly diagnosed with Parkinson's disease (PD).

Background: Evidence for a pathophysiologic role of inflammation in PD is growing. However, several key gaps remain as to the role of inflammation in PD, including the extent of immune activation at early stages, potential effects of PD treatments on inflammation and whether pro-inflammatory signals are associated with clinical features and/or predict more rapid progression.

Methods: We enrolled subjects with de novo PD (n = 58) and age-matched controls (n = 62). Subjects underwent clinical assessments, including the Movement Disorder Society-United Parkinson's Disease rating scale (MDS-UPDRS). Comprehensive cognitive assessment meeting MDS Level II criteria for mild cognitive impairment testing was performed. Blood was obtained for flow cytometry and cytokine/chemokine analyses. Subjects underwent imaging with F-DPA-714, a translocator protein 18kd ligand, and lumbar puncture if eligible and consented.

Results: Baseline demographics and medical history were comparable between groups. PD subjects showed significant differences in University of Pennsylvania Smell Identification Test, Schwab and England Activities of Daily Living, Scales for Outcomes in PD autonomic dysfunction, and MDS-UPDRS scores. Cognitive testing demonstrated significant differences in cognitive composite, executive function, and visuospatial domain scores at baseline. Positron emission tomography imaging showed increased F-DPA-714 signal in PD subjects. F-DPA-714 signal correlated with several cognitive measures and some chemokines.

Conclusions: F-DPA-714 imaging demonstrated increased central inflammation in de novo PD subjects compared to controls. Longitudinal follow-up will be important to determine whether the presence of inflammation predicts cognitive decline. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Citing Articles

From Diagnosis to Treatment: A Comprehensive Review of Biomarkers and Therapeutic Advances in Parkinson's Disease.

Rangwala H, Fatima H, Syed A, Abbas S, Rangwala B Ann Neurosci. 2025; 32(1):51-57.

PMID: 40017568 PMC: 11863227. DOI: 10.1177/09727531231200733.

Targeting mitophagy in neurodegenerative diseases.

Antico O, Thompson P, Hertz N, Muqit M, Parton L Nat Rev Drug Discov. 2025; .

PMID: 39809929 DOI: 10.1038/s41573-024-01105-0.

Plasma fibronectin is a prognostic biomarker of disability in Parkinson's disease: a prospective, multicenter cohort study.

Zhu S, Li H, Huang Z, Zeng Y, Huang J, Li G NPJ Parkinsons Dis. 2025; 11(1):1.

PMID: 39747089 PMC: 11697031. DOI: 10.1038/s41531-024-00865-1.

Brain temperature, brain metabolites, and immune system phenotypes in temporal lobe epilepsy.

Mueller C, Hong H, Sharma A, Qin H, Benveniste E, Szaflarski J Epilepsia Open. 2024; 9(6):2454-2466.

PMID: 39470707 PMC: 11633690. DOI: 10.1002/epi4.13082.

Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.

Wilson E, Umans J, Swarovski M, Minhas P, Midttun O, Ulvik A Res Sq. 2024; .

PMID: 39399688 PMC: 11469709. DOI: 10.21203/rs.3.rs-4980210/v1.

References

Sekine T, Ter Voert E, Warnock G, Buck A, Huellner M, Veit-Haibach P . Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain 18F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. J Nucl Med. 2016; 57(12):1927-1932. DOI: 10.2967/jnumed.116.175398. View

Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O . Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. Sci Rep. 2018; 8(1):13276. PMC: 6125576. DOI: 10.1038/s41598-018-31517-z. View

Nutma E, Fancy N, Weinert M, Tsartsalis S, Marzin M, Muirhead R . Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Nat Commun. 2023; 14(1):5247. PMC: 10462763. DOI: 10.1038/s41467-023-40937-z. View

Foo H, Mak E, Yong T, Wen M, Chander R, Au W . Progression of subcortical atrophy in mild Parkinson's disease and its impact on cognition. Eur J Neurol. 2016; 24(2):341-348. DOI: 10.1111/ene.13205. View

Wijeyekoon R, Kronenberg-Versteeg D, Scott K, Hayat S, Kuan W, Evans J . Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. Brain Behav Immun. 2020; 87:473-488. PMC: 7613010. DOI: 10.1016/j.bbi.2020.01.018. View

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley R . Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016; 139(Pt 4):1252-64. DOI: 10.1093/brain/aww017. View

Kustrimovic N, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F . Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Sci Rep. 2016; 6:33738. PMC: 5031979. DOI: 10.1038/srep33738. View

Li M, Zhou L, Sun X, Yang Y, Zhang C, Wang T . Dopamine, a co-regulatory component, bridges the central nervous system and the immune system. Biomed Pharmacother. 2021; 145:112458. DOI: 10.1016/j.biopha.2021.112458. View

Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, Chalimoniuk M . Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008; 441(2):158-62. DOI: 10.1016/j.neulet.2008.06.040. View

10.

Qin H, Buckley J, Li X, Liu Y, Fox 3rd T, Meares G . Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. J Neurosci. 2016; 36(18):5144-59. PMC: 6123006. DOI: 10.1523/JNEUROSCI.4658-15.2016. View

11.

Ahmadi Rastegar D, Ho N, Halliday G, Dzamko N . Parkinson's progression prediction using machine learning and serum cytokines. NPJ Parkinsons Dis. 2019; 5:14. PMC: 6658482. DOI: 10.1038/s41531-019-0086-4. View

12.

Liu S, Qiao H, Song T, Liu X, Yao Y, Zhao C . Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study. J Neuroinflammation. 2022; 19(1):209. PMC: 9422161. DOI: 10.1186/s12974-022-02574-z. View

13.

Gerhard A, Schwarz J, Myers R, Wise R, Banati R . Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005; 24(2):591-5. DOI: 10.1016/j.neuroimage.2004.09.034. View

14.

McGeer P, Itagaki S, Akiyama H, McGeer E . Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988; 24(4):574-6. DOI: 10.1002/ana.410240415. View

15.

Alvarez-Luquin D, Arce-Sillas A, Leyva-Hernandez J, Sevilla-Reyes E, Boll M, Montes-Moratilla E . Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved. J Neuroinflammation. 2019; 16(1):212. PMC: 6849192. DOI: 10.1186/s12974-019-1606-1. View

16.

Zhang P, Gao F . Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies. J Neurol. 2021; 269(5):2304-2314. DOI: 10.1007/s00415-021-10877-z. View

17.

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T . Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett. 1996; 211(1):13-6. DOI: 10.1016/0304-3940(96)12706-3. View

18.

Hamza T, Zabetian C, Tenesa A, Laederach A, Montimurro J, Yearout D . Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010; 42(9):781-5. PMC: 2930111. DOI: 10.1038/ng.642. View

19.

Wimberley C, Lavisse S, Brulon V, Peyronneau M, Leroy C, Bodini B . Impact of Endothelial 18-kDa Translocator Protein on the Quantification of F-DPA-714. J Nucl Med. 2017; 59(2):307-314. DOI: 10.2967/jnumed.117.195396. View

20.

Scalzo P, Kummer A, Cardoso F, Teixeira A . Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett. 2009; 468(1):56-8. DOI: 10.1016/j.neulet.2009.10.062. View